Panagora Asset Management Inc. Acquires New Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Panagora Asset Management Inc. bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAXFree Report) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 391,729 shares of the biopharmaceutical company’s stock, valued at approximately $5,786,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its position in shares of Dynavax Technologies by 23.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 41,346 shares of the biopharmaceutical company’s stock worth $611,000 after buying an additional 7,731 shares during the period. Oregon Public Employees Retirement Fund lifted its stake in Dynavax Technologies by 2.7% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 38,254 shares of the biopharmaceutical company’s stock valued at $565,000 after acquiring an additional 1,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Dynavax Technologies by 8.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,820 shares of the biopharmaceutical company’s stock worth $1,194,000 after acquiring an additional 6,339 shares during the last quarter. BluePath Capital Management LLC bought a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $33,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Dynavax Technologies by 20.5% in the third quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock valued at $20,083,000 after purchasing an additional 231,731 shares during the last quarter. Institutional investors and hedge funds own 99.13% of the company’s stock.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, COO David F. Novack sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $14.12, for a total value of $282,400.00. Following the sale, the chief operating officer now owns 3,187 shares in the company, valued at $45,000.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, COO David F. Novack sold 9,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $14.45, for a total transaction of $130,050.00. Following the completion of the sale, the chief operating officer now owns 3,187 shares in the company, valued at approximately $46,052.15. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO David F. Novack sold 20,000 shares of Dynavax Technologies stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $14.12, for a total transaction of $282,400.00. Following the sale, the chief operating officer now directly owns 3,187 shares of the company’s stock, valued at approximately $45,000.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 70,500 shares of company stock worth $1,006,150. Insiders own 2.62% of the company’s stock.

Wall Street Analyst Weigh In

DVAX has been the subject of several recent research reports. StockNews.com started coverage on shares of Dynavax Technologies in a report on Thursday, October 5th. They set a “hold” rating for the company. HC Wainwright increased their price objective on shares of Dynavax Technologies from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Finally, JMP Securities raised their price objective on Dynavax Technologies from $25.00 to $27.00 and gave the company a “market outperform” rating in a report on Friday, November 3rd.

View Our Latest Analysis on DVAX

Dynavax Technologies Trading Down 1.3 %

NASDAQ DVAX opened at $13.99 on Thursday. Dynavax Technologies Co. has a 12 month low of $9.42 and a 12 month high of $15.15. The company has a current ratio of 15.40, a quick ratio of 14.49 and a debt-to-equity ratio of 0.37. The stock has a 50 day moving average of $13.74 and a 200-day moving average of $13.99. The company has a market cap of $1.81 billion, a PE ratio of 35.87 and a beta of 1.30.

Dynavax Technologies (NASDAQ:DVAXGet Free Report) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. Dynavax Technologies had a net margin of 16.92% and a return on equity of 10.51%. The firm had revenue of $69.51 million during the quarter, compared to analysts’ expectations of $62.15 million. On average, equities research analysts anticipate that Dynavax Technologies Co. will post -0.15 EPS for the current fiscal year.

Dynavax Technologies Company Profile

(Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Read More

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAXFree Report).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.